Search clinical trials for: ISIS EIF4E Rx

Total 381 results

Ionis Pharmaceuticals, Inc.
Bayer

Completed

A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis

End-stage Renal Disease (ESRD)

Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS-APO(a)Rx in Participants With High Lipoprotein(a)

Elevated Lipoprotein(a)

Netherlands, United Kingdom, Denmark, Germany, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel (NSCLC)

Non-small Cell Lung Cancer

United States, Hungary, Poland, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Rheumatoid Arthritis

Canada, Russian Federation
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies (SHINE)

Spinal Muscular Atrophy

United States, Spain, Germany, United Kingdom, Australia, Japan, Canada, Belgium, France, Hong Kong, Italy, Korea, Republic of, Sweden, Turkey
Biogen

Completed

An Open-label Safety, Tolerability, and Dose-range Finding Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) (SMNRx)

Spinal Muscular Atrophy

United States
Biogen

Completed

A Study to Assess the Efficacy, Safety and Pharmacokinetics of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (SMA)

Spinal Muscular Atrophy

United States, Canada
Biogen

Terminated

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy (ENDEAR)

Spinal Muscular Atrophy

Korea, Republic of, United States, Spain, Canada, Germany, Australia, Japan, Sweden, Belgium, France, Italy, Turkey, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Extension Study Assessing Long Term Safety and Efficacy of IONIS-TTR Rx in Familial Amyloid Polyneuropathy (FAP)

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Biogen

Completed

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy Who Previously Participated in ISIS 396443-CS1 (NCT01494701)

Spinal Muscular Atrophy

United States
Ionis Pharmaceuticals, Inc.

Completed

Efficacy and Safety of Inotersen in Familial Amyloid Polyneuropathy

Amyloidosis | Familial Amyloid Polyneuropathy | FAP | TTR | Transthyretin

New Zealand, United States, Spain, Argentina, Brazil, France, Germany, Italy, Portugal, United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Antiarrhythmic and Symptomatic Effect of ISIS CRP Rx Targeting CRP in Paroxysmal Atrial Fibrillation (ASET)

Paroxysmal Atrial Fibrillation

United Kingdom
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Hypertriglyceridemia

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Docetaxel and Prednisone (CRPC)

Castrate-Resistant Prostate Cancer

United States, Puerto Rico, Hungary, Romania, Russian Federation, Poland
Biogen

Completed

A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA) (CHERISH)

Spinal Muscular Atrophy

United States, Germany, Spain, Canada, France, Hong Kong, Italy, Japan, Korea, Republic of, Sweden
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ISIS 443139 in Participants With Early Manifest Huntington's Disease

Huntington's Disease

Canada, United Kingdom, Germany
Abbott Medical Devices

Completed

Carotid Artery Stenting Outcomes in the Standard Risk Population for Carotid Endarterectomy (CANOPY)

Stroke | Carotid Artery Disease | Amaurosis Fugax | Transient Ischemic Attack (TIA)

United States
Abbott Medical Devices

Completed

CAPTURE 2 Post-Marketing Registry (CAPTURE 2)

Carotid Artery Disease

United States
Atrium Medical Corporation

Completed

Renal Stent Placement for the Treatment of Renal Artery Stenosis in Patients With Resistant Hypertension (ARTISAN)

Hypertension, Renovascular | Renal Artery Stenosis

United States
Biogen

Completed

An Open-label Safety, Tolerability and Dose-Range Finding Study of Multiple Doses of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy

Spinal Muscular Atrophy

United States
Vielight Inc.

Completed

Vielight Neuro RX Gamma - Feasibility Pilot

Alzheimer Disease

Canada
Abbott Medical Devices

Completed

CHOICE: Carotid Stenting For High Surgical-Risk Patients

Carotid Artery Disease

United States
Vielight Inc.

Suspended

Neuro RX Gamma - Pivotal Phase

Alzheimer Disease

Canada, United States
Biogen

Terminated

A Study to Assess the Safety and Tolerability of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA). (EMBRACE)

Spinal Muscular Atrophy

United States, Germany
Ionis Pharmaceuticals, Inc.

Completed

A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients (FGFR4-CS2)

Obesity

United States
Unity Health Toronto

Recruiting

Neuro RX Gamma for Amnestic Mild Cognitive Impairment (aMCI)

MCI | Amnestic Mild Cognitive Disorder

Canada
Processa Pharmaceuticals

Completed

Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies

Solid Tumor | Metastatic Bladder Cancer

United States
Kaiser Permanente
Unity Health

Active, not recruiting

Park Rx and Physical Activity Among Low-income Children (ParkRx)

Physical Activity | Mental Health Wellness 1

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Patients With Type 2 Diabetes

Type 2 Diabetes

United States
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability and Efficacy of ISIS-GCGRRx in Type 2 Diabetes

Type 2 Diabetes Mellitus

United States, South Africa
C.T. Development America, Inc.

Completed

A Study of RX-10045 in the Treatment of Dry Eye Disease

Dry Eye Syndrome

United States
Ionis Pharmaceuticals, Inc.

Completed

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Canada
Ionis Pharmaceuticals, Inc.

Completed

Safety, Tolerability, and Activity of ISIS 113715 in People With Type 2 Diabetes Mellitus Who Have Not Received Prior Treatment

Type 2 Diabetes Mellitus

Russian Federation, Poland
Vielight Inc.

Not yet recruiting

A Pilot Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment

Post COVID-19 Cognitive Impairment

United States
Ionis Pharmaceuticals, Inc.
Elan Pharmaceuticals; Hepasense

Completed

ISIS 14803-CS2, Treatment With ISIS 14803, Administered IV in Patients With Chronic Hepatitis C Virus Infections

Hepatitis C, Chronic

United States
Ionis Pharmaceuticals, Inc.

Completed

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Type 2 Diabetes Mellitus

Poland, Romania, Russian Federation
Ionis Pharmaceuticals, Inc.

Completed

Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes

Type 2 Diabetes

Austria
Akcea Therapeutics
Ionis Pharmaceuticals, Inc.

Completed

Study of ISIS 681257 in Patients With Renal Impairment Compared to Healthy Patients

Renal Impairment

United States, Canada
European Organisation for Research and Treatment...

Completed

ISIS 3521 in Treating Patients With Advanced, Unresectable, or Metastatic Non-small Cell Lung Cancer or Unresectable or Metastatic Melanoma

Lung Cancer | Melanoma (Skin)

France, Netherlands, Norway, Belgium, Switzerland, United Kingdom, Germany, Denmark, Austria
Ionis Pharmaceuticals, Inc.

Completed

Safety Study of ISIS 325568 in Healthy Volunteers

Type 2 Diabetes Mellitus

Netherlands
University Hospital, Ghent

Completed

Long Term Follow-up of the "Stryker Dacron and Trevira Ligament" for Anterior Cruciate Ligament (ACL) Repair

Replacement | ACL Rupture

Belgium
Intermountain Health Care, Inc.
Savvysherpa, Inc.

Completed

Patient Ambulation in Post-Op Recovery

Physical Activity

United States
Vielight Inc.

Active, not recruiting

Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms (COVIDLight)

COVID-19

United States, Canada
HistoSonics, Inc.

Terminated

Safety and Initial Efficacy Study of the Vortx Rx for Treatment of Benign Prostatic Hyperplasia (US)

Benign Prostatic Hyperplasia (BPH)

United States
Phoenix VA Health Care System
Rouxbe Online Culinary School; Carl T. Hayden Medical Research Foundation

Completed

Pilot Study on the Effects of a Plant-Strong Diet on Cardiovascular Risk Factors

Diabetes | Hyperlipidemias | Overweight and Obesity

United States
C.T. Development America, Inc.

Completed

Evaluation of the Onset and Duration of Action of RX-10045 in Allergic Conjunctivitis

Allergic Conjunctivitis

United States
Boston Scientific Corporation

Completed

Esophageal Fully Covered Metal Stents in Caustic Strictures Study

Refractory Benign Esophageal Strictures Caused by Caustic Ingestion

India
Abbott Medical Devices
Guidant Corporation

Completed

Post-Approval Study of the Guidant Carotid Stent Systems and Embolic Protection Systems: CAPTURE

Atherosclerotic Disease, Carotid

United States
Rexahn Pharmaceuticals, Inc.

Completed

Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED)

Erectile Dysfunction (ED)

United States

Search clinical trials for: ISIS EIF4E Rx

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Japan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations